IONIS PHARMACEUTICALS INC Quarterly Costs and Expenses in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Ionis Pharmaceuticals Inc quarterly/annual Costs and Expenses history and growth rate from Q1 2018 to Q2 2024.
  • Ionis Pharmaceuticals Inc Costs and Expenses for the quarter ending June 30, 2024 was $291M, a 4.57% increase year-over-year.
  • Ionis Pharmaceuticals Inc Costs and Expenses for the twelve months ending June 30, 2024 was $1.18B, a 6.93% increase year-over-year.
  • Ionis Pharmaceuticals Inc annual Costs and Expenses for 2023 was $1.14B, a 14.4% increase from 2022.
  • Ionis Pharmaceuticals Inc annual Costs and Expenses for 2022 was $998M, a 18.7% increase from 2021.
  • Ionis Pharmaceuticals Inc annual Costs and Expenses for 2021 was $841M, a 6.74% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.18B $291M +$12.7M +4.57% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $1.17B $269M +$24.3M +9.95% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $1.14B $331M -$29.3M -8.14% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $1.17B $287M +$68.6M +31.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $1.1B $279M +$59.3M +27% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $1.04B $245M +$45.2M +22.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $998M $360M +$141M +64% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $857M $219M -$21K -0.01% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $857M $219M +$20.6M +10.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $836M $199M -$4.16M -2.04% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $841M $219M -$93.5M -29.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-22
Q3 2021 $934M $219M +$22.3M +11.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $912M $199M +$1.43M +0.72% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $910M $204M +$9.08M +4.67% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $901M $313M +$79.9M +34.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-25
Q3 2020 $821M $197M +$31.2M +18.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $790M $197M +$14.7M +8.02% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $776M $194M +$18.8M +10.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $757M $233M +$51.7M +28.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 $705M $165M +$1.4M +0.86% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $704M $183M +$14.6M +8.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $689M $176M +$28M +18.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $661M $181M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 $164M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 $168M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 $148M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.